Population pharmacokinetic–pharmacodynamic analysis for eribulin mesilate-associated neutropenia

AIMS: Eribulin mesilate is an inhibitor of microtubule dynamics that is approved for the treatment of late-stage metastatic breast cancer. Neutropenia is one of the major dose-limiting adverse effects of eribulin. The objective of this analysis was to develop a population pharmacokinetic–pharmacodyn...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: van Hasselt, J G Coen, Gupta, Anubha, Hussein, Ziad, Beijnen, Jos H, Schellens, Jan H M, Huitema, Alwin D R
Format: Artigo
Idioma:Inglês
Publicat: Blackwell Science Inc 2013
Matèries:
Pharmacokinetics
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3769668/
https://ncbi.nlm.nih.gov/pubmed/23601153
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.12143
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars